Filing Details

Accession Number:
0000914475-24-000123
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-05-16 16:55:21
Reporting Period:
2024-05-14
Accepted Time:
2024-05-16 16:55:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
914475 Neurocrine Biosciences Inc NBIX Biological Products, (No Disgnostic Substances) (2836) 330525145
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1123343 A Gary Lyons 12780 El Camino Real
San Diego CA 92130
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-05-14 12,500 $42.76 129,447 No 4 M Direct
Common Stock Disposition 2024-05-14 12,500 $135.63 116,947 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option Disposition 2024-05-14 12,500 $42.76 12,500 $42.76
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
12,500 2025-05-28 No 4 M Direct
Footnotes
  1. Reflects a decrease of 76,750 shares from the amount previously reported as beneficially owned, which was recently discovered to be overstated due to an administrative oversight.
  2. 110,964 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power.
  3. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2024.
  4. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $134.78 to $137.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  5. The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options will expire ten years from the date of grant on May 28, 2025.